(2S)-2-[[(2S)-2-benzamidopropanoyl]amino]-5-(diaminomethylideneazaniumyl)pentanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[(2S)-2-benzamidopropanoyl]amino]-5-(diaminomethylideneazaniumyl)pentanoate
• 化学式: C16H23N5O4
• 分子量: 349.38
• InChiKey: FDSPJMDEWGLXKT-JQWIXIFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  160
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• Novel nucleic acid molecules and polypeptides encoding baboon TAFI
  申请人：——

  公开号：US20030215850A1

  公开（公告）日：2003-11-20

  The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention. Such agonist or antagonist compounds may be useful in the treatment of various blood clotting disorders and conditions requiring hemostatic control such as hemophilia or various thrombotic diseases such as deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation and recurrent thrombosis following stroke or myocardial infarction.

  本发明涉及新型狒狒核酸分子和由这种核酸分子编码的蛋白质和多肽或其退化变体的分离和鉴定，这些蛋白质和多肽包括新型狒狒凝血酶活化纤溶抑制剂或 "TAFI "酶分子。由于本发明的新型狒狒 TAFI 蛋白和多肽可抑制血凝块的分解，因此可用于治疗需要调节或促进凝血的血液疾病，如血友病或冯-威廉氏病，或在需要调节或促进凝血的其他情况下，如创伤。本发明的序列还可用于筛选方法，以鉴定可调节狒狒 TAFI 核酸表达和/或本发明狒狒 TAFI 蛋白和多肽活性的化合物。这种激动剂或拮抗剂化合物可用于治疗各种凝血障碍和需要止血控制的疾病，如血友病或各种血栓性疾病，如深静脉血栓、冠状动脉疾病、伴有心房颤动的中风和中风或心肌梗塞后的复发性血栓形成。
• NOVEL NUCLEIC ACID MOLECULES AND POLYPEPTIDES ENCODING BABOON TAFI
  申请人：Tamura K. James

  公开号：US20060183686A1

  公开（公告）日：2006-08-17

  The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention. Such agonist or antagonist compounds may be useful in the treatment of various blood clotting disorders and conditions requiring hemostatic control such as hemophilia or various thrombotic diseases such as deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation and recurrent thrombosis following stroke or myocardial infarction.

  本发明涉及新型狒狒核酸分子和由这种核酸分子编码的蛋白质和多肽或其退化变体的分离和鉴定，这些蛋白质和多肽包括新型狒狒凝血酶活化纤溶抑制剂或 "TAFI "酶分子。由于本发明的新型狒狒 TAFI 蛋白和多肽可抑制血凝块的分解，因此可用于治疗需要调节或促进凝血的血液疾病，如血友病或冯-威廉氏病，或在需要调节或促进凝血的其他情况下，如创伤。本发明的序列还可用于筛选方法，以鉴定可调节狒狒 TAFI 核酸表达和/或本发明狒狒 TAFI 蛋白和多肽活性的化合物。这种激动剂或拮抗剂化合物可用于治疗各种凝血障碍和需要止血控制的疾病，如血友病或各种血栓性疾病，如深静脉血栓、冠状动脉疾病、伴有心房颤动的中风和中风或心肌梗塞后的复发性血栓形成。
• NOVEL NUCLEIC ACID MOLECULES AND POLYPEPTIDES ENCODING BABOON TAFI
  申请人：Bristol-Myers Squibb Company

  公开号：EP1572906A2

  公开（公告）日：2005-09-14
• EP1572906A4
  申请人：——

  公开号：EP1572906A4

  公开（公告）日：2008-05-28
• IDENTIFICATION OF HUMAN MOUSE DOUBLE MINUTE 2 HOMOLOG NUCLEOTIDE SEQUENCES
  申请人：RYOGEN LLC

  公开号：US20130071845A1

  公开（公告）日：2013-03-21

  The invention is directed to isolated genomic polynucleotide fragments that encode human carboxypeptidase M and human mouse double minute 2 homolog, vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human carboxypeptidase M and human mouse double minute 2 homolog and to diagnose, treat, prevent and/or ameliorate a pathological disorder.